Virology Journal, published by BMC, stands as a prominent open-access platform since 2004, dedicated to advancing the field of virology and infectious diseases. With its E-ISSN: 1743-422X, this journal is based in the United Kingdom and strives to disseminate high-quality research that enhances our understanding of viral pathogens and their interactions with hosts. Recognized with a Q1 classification in the category of Infectious Diseases and a Q2 in Virology for 2023, Virology Journal holds significant standing in the academic community, ranking #82/344 in Medicine - Infectious Diseases and #26/80 in Immunology and Microbiology - Virology. Its commitment to open access ensures that cutting-edge research is freely available to researchers, professionals, and students worldwide, fostering collaboration and innovation in the fight against viral diseases. The journal aims to publish original research articles, reviews, and commentaries that will stimulate discourse and spark new ideas within the virology community.

REVIEWS IN MEDICAL VIROLOGY is a premier academic journal published by Wiley, dedicated to advancing the field of virology and infectious diseases. Established in 1991, this journal has gained a reputable standing, holding a Q1 ranking in both Infectious Diseases and Virology as of 2023, with impressive Scopus rankings placing it at #17 out of 344 in the realm of Medicine - Infectious Diseases, and #8 out of 80 in Immunology and Microbiology - Virology. This reflects its substantial impact factor and contribution to ongoing research and scholarship. While it is not an Open Access publication, REVIEWS IN MEDICAL VIROLOGY offers vital insights and comprehensive reviews that cater to a diverse audience including researchers, healthcare professionals, and students pursuing knowledge in medical virology. The journal serves as a vital resource for understanding the complexities of viral pathogens and the evolving landscape of antiviral therapeutics, making it an essential read for those poised at the forefront of infectious disease research.

ANTIVIRAL RESEARCH, published by Elsevier, stands at the forefront of the study of antiviral agents and therapy, with a dedicated focus on advancing the understanding of viral infections and their mechanisms. The journal is recognized within the top tier of academic publications, belonging to the prestigious Q1 category in both Pharmacology and Virology as of 2023, ranking 12th out of 313 in Pharmacology and 11th out of 80 in Virology according to Scopus metrics, reflecting its significant impact in the field. With a long-standing history since its inception in 1959, it continues to serve as an essential platform for researchers and health professionals alike, sharing critical findings that drive innovation in antiviral therapeutics. Although it does not currently offer open access options, the journal’s rigorous peer-review process ensures that every published article meets high academic standards, providing invaluable insights for those dedicated to enhancing public health through virology research.

Tumour Virus Research, an esteemed journal published by Elsevier, serves as a vital resource in the fields of cancer research, infectious diseases, and virology. With an impact factor reflective of its influence and recognized as a Q2 journal in multiple categories as of 2023, it rigorously presents high-impact research dedicated to the understanding of viral pathogens in tumorigenesis. Since its transition to an Open Access model in 2021, the journal has enhanced accessibility, empowering researchers and the academic community globally to explore cutting-edge findings. The journal covers a broad scope, encompassing the intricate interactions between viruses and cancer biology, which is crucial for developing novel therapeutic strategies. With a commitment to advancing scientific knowledge, Tumour Virus Research welcomes submissions that push the boundaries of current understanding and contribute to the ongoing battle against virus-mediated cancers, making it an indispensable publication for professionals, researchers, and students in the field.

ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.

Virus Evolution is a premier open access journal published by Oxford University Press, dedicated to advancing the understanding of viral dynamics and evolutionary trends. Established in 2015, it has quickly ascended to a leading position in the fields of Microbiology and Virology, achieving a remarkable Q1 ranking in both categories for 2023. With its impactful research output, it ranks #27 out of 182 in Microbiology and #15 out of 80 in Virology, placing it in the top percentiles of the Scopus rankings. The journal serves as a vital resource for researchers, professionals, and students, providing a platform for the dissemination of innovative research that explores the genetic and ecological aspects of viruses. By embracing an open access model, Virus Evolution ensures that its high-quality content is accessible to a global audience, fostering collaboration and enhancing the impact of virology research worldwide.

Advances in Virology, an esteemed journal published by HINDAWI LTD, serves as a pivotal platform for cutting-edge research in the field of virology and infectious diseases. With its ISSN 1687-8639 and E-ISSN 1687-8647, the journal has been a significant contributor to the scientific community since its initiation as an Open Access resource in 2009, allowing researchers from around the globe to access groundbreaking findings without barriers. Operating out of the United States and recognized for its commitment to high-quality research, the journal's relevance is underscored by its ranking in the Q3 category for Infectious Diseases and Q4 for Virology as of 2023. The time frame of publications spans from 2009 to 2024, reflecting a continuous commitment to exploring the evolving landscape of virology. This journal not only promotes the dissemination of novel insights and methodologies but also fosters collaboration and innovation within the scientific community, making it an invaluable resource for researchers, professionals, and students alike.

Journal of Virology is a premier scholarly journal dedicated to advancing the field of virology, focusing on the molecular mechanisms of virus-host interactions, viral pathogenesis, and the latest therapeutic and vaccine developments. Published by the American Society for Microbiology, this esteemed journal has been a cornerstone for researchers since its inception in 1967, providing a platform for high-quality, peer-reviewed research. With a commendable impact factor indicative of its relevance and influence, the journal is categorized in the top quartile (Q1) for Virology, Microbiology, and Insect Science, reflecting its significance in these fields. Researchers can access a wealth of studies and findings that shape our understanding of viruses and their interactions with hosts, highlighting its role in both basic and applied sciences. Positioned in the United States, the Journal of Virology serves a global audience, ensuring that cutting-edge discoveries reach professionals, students, and academics alike. Join the conversation as we explore the complexities of virology and its implications for human health and disease.

VIROLOGIE is a prominent international journal dedicated to advancing the field of virology and infectious diseases, published by John Libbey Eurotext Ltd. Since its inception in 1997, this journal has provided a platform for researchers and professionals to disseminate their findings on various aspects of virology, including the pathogenesis, epidemiology, and treatment of viral infections. Despite its current ranking in Q4 for both Infectious Diseases and Virology categories, the journal remains a valuable resource for emerging research and novel insights. The ISSN for the journal is 1267-8694, and it is based in France. VIROLOGIE is committed to upholding rigorous academic standards and fosters an inclusive scholarly community, making it an essential read for those pursuing knowledge and advancements in the ever-evolving landscape of virology. While the journal does not currently offer open access options, it continues to contribute significantly to the global discourse on viral research through its diverse range of published studies.

Frontiers in Virology, published by FRONTIERS MEDIA SA, is an innovative open-access journal dedicated to advancing the understanding of viral biology, pathogenesis, surveillance, and control strategies. With the rapid evolution of viral threats, this journal serves as a critical platform for researchers, professionals, and students to disseminate and access high-quality research, reviews, and perspectives in virology. The journal places a strong emphasis on interdisciplinary approaches, promoting collaborative efforts that drive breakthroughs in the field. While the specific impact factor and H-index details are currently unavailable, Frontiers in Virology is committed to rigorous peer review and integrity in scientific publishing. Authors and readers will benefit from the extensive reach provided by open access, making groundbreaking insights available to a global audience, thus contributing significantly to the ongoing dialogue in virology and public health.